{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-076066","form_type":"8-K","ticker":"UNCY","cik":"0001766140","company_name":"Unicycive Therapeutics, Inc.","filed_at":"2025-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.917885+00:00","generated_at":"2026-05-17T13:19:50.924181+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Unicycive Q2 net loss $6.4M; requests FDA Type A meeting for CRL on OLC","bullets":["Net loss of $6.4M vs net income of $3.0M in Q2 2024; R&D expenses down to $1.8M.","Cash and equivalents $22.3M as of June 30, 2025; runway expected into H2 2026.","Type A meeting requested with FDA to resolve CRL for oxylanthanum carbonate (OLC).","Pivotal OLC data published in CJASN: >90% patients achieved phosphate control with low pill burden."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-076066","json":"https://secwatch.observer/filing/0001213900-25-076066.json","markdown":"https://secwatch.observer/filing/0001213900-25-076066.md","text":"https://secwatch.observer/filing/0001213900-25-076066.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1766140/000121390025076066/0001213900-25-076066-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1766140/000121390025076066/ea0253163-8k_unicy.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T13:19:50.924181+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}